{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:18:08Z","timestamp":1779164288383,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.thromres.2019.02.022","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T16:31:33Z","timestamp":1550853093000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?"],"prefix":"10.1016","volume":"176","author":[{"given":"Christos","family":"Mantis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2019.02.022_bb0005","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","article-title":"Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study","volume":"44","author":"Bj\u00f6rck","year":"2013","journal-title":"Stroke."},{"key":"10.1016\/j.thromres.2019.02.022_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2019.02.022_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2019.02.022_bb0020","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.amjcard.2015.07.041","article-title":"Prevalence and implications of subclinical coronary artery disease in patients with atrial fibrillation","volume":"116","author":"Chaikriangkrai","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.thromres.2019.02.022_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2019.02.022_bb0030","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jcin.2017.02.028","article-title":"Prevalence, management, and long-term (6-year) outcomes of atrial fibrillation among patients receiving drug eluting coronary stents","volume":"10","author":"Choi","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.thromres.2019.02.022_bb0035","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2019.02.022_bb0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2019.02.022_bb0045","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.02.022_bb0050","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.02.022_bb0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10557-017-6730-5","article-title":"Triple antithrombotic therapy in atrial fibrillation patients undergoing PCI: a fading role","volume":"31","author":"Alexopoulos","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.thromres.2019.02.022_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.02.022_bb0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/CIRCULATIONAHA.116.025923","article-title":"O PIONEERs! The beginning of the end of full-dose triple therapy with warfarin?","volume":"135","author":"Bhatt","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.thromres.2019.02.022_bb0070","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2019.02.022_bb0075","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jacc.2014.06.1193","article-title":"Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review","volume":"64","author":"Dewilde","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2019.02.022_bb0080","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.thromres.2019.02.022_bb0085","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","article-title":"Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period","volume":"30","author":"Schulz","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2019.02.022_bb0090","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation","volume":"138","author":"Pisters","year":"2010","journal-title":"CHEST."},{"key":"10.1016\/j.thromres.2019.02.022_bb0095","first-page":"1","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"00","author":"Neumann","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2019.02.022_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report","author":"Lip","year":"2018","journal-title":"CHEST"},{"key":"10.1016\/j.thromres.2019.02.022_bb0105","doi-asserted-by":"crossref","unstructured":"Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2018. doi:https:\/\/doi.org\/10.1093\/europace\/euy174.","DOI":"10.1093\/europace\/euy174"},{"key":"10.1016\/j.thromres.2019.02.022_bb0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with Oral anticoagulation undergoing percutaneous coronary intervention - a north American perspective\u20132018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.thromres.2019.02.022_bb0115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cjca.2017.12.012","article-title":"2018 Canadian Cardiovascular Society\/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.thromres.2019.02.022_bb0120","doi-asserted-by":"crossref","first-page":"24376","DOI":"10.1038\/srep24376","article-title":"Major bleeding in patients with non-Valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores","volume":"6","author":"Proietti","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2019.02.022_bb0125","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation","volume":"62","author":"Rold\u00e1n","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2019.02.022_bb0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.thromres.2019.02.022_bb0135","doi-asserted-by":"crossref","unstructured":"Golwala HB, Cannon CP, Steg PG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur. Heart J. 2018; 39:1726-1735a.doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehy162.","DOI":"10.1093\/eurheartj\/ehy162"},{"key":"10.1016\/j.thromres.2019.02.022_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","article-title":"Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy","volume":"135","author":"Gibson","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.thromres.2019.02.022_bb0145","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2019.02.022_bb0150","doi-asserted-by":"crossref","unstructured":"D'Ascenzo F, Taha S, Moretti C, et al. Metaanalysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 2015; 115:1185\u20131193. doi: https:\/\/doi.org\/10.1016\/j.amjcard.2015.02.003.","DOI":"10.1016\/j.amjcard.2015.02.003"},{"key":"10.1016\/j.thromres.2019.02.022_bb0155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.amjmed.2015.12.026","article-title":"Triple vs dual antithrombotic therapy inPatients with atrial fibrillation and coronary artery disease","volume":"129","author":"Lopes","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2019.02.022_bb0160","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2019.02.022_bb0165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ahj.2010.06.004","article-title":"Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis","volume":"160","author":"Aradi","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2019.02.022_bb0170","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.02.022_bb0175","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.thromres.2019.02.022_bb0180","first-page":"E457","article-title":"Subgroup analysis from the RE-DUAL PCI trial: dual antithrombotic therapy with dabigatran in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"136","author":"Oldgren","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2019.02.022_bb0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10557-018-6795-9","article-title":"Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: a systematic review and meta-analysis","volume":"32","author":"Andreou","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.thromres.2019.02.022_bb0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","volume":"200","author":"Lopes","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2019.02.022_bb0195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention with stent placement: rationale and design of the ENTRUST-AF PCI Trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2019.02.022_bb0200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cct.2015.05.012","article-title":"Rationale and design of the RT-AF study: combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention","volume":"43","author":"Gao","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.thromres.2019.02.022_bb0205","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cct.2014.12.002","article-title":"Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS","volume":"40","author":"Lu","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.thromres.2019.02.022_bb0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10557-018-6789-7","article-title":"Contemporary antithrombotic treatment in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: rationale and design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry","volume":"32","author":"Xanthopoulou","year":"2018","journal-title":"Cardiovasc. Drugs Ther."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819300672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819300672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T09:04:02Z","timestamp":1553504642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384819300672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":42,"alternative-id":["S0049384819300672"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2019.02.022","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2019.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}